CN Patent

CN111777595A — 一种环己烷甲酰胺类化合物的新晶型及其制备方法

Assigned to Shanghai Acebright Pharmaceuticals Group Co ltd · Expires 2020-10-16 · 6y expired

What this patent protects

本发明提供了(1S,4R)‑N‑((S)‑1‑(6‑(4‑氟‑1H‑吡唑‑1‑基)吡啶‑3‑基)乙基)‑1‑甲氧基‑4‑(4‑甲基‑6‑((5‑甲基‑1H‑吡唑‑3‑基)氨基)嘧啶‑2‑基)环己烷甲酰胺(式(I)化合物)的新晶型及其制备方法。

USPTO Abstract

本发明提供了(1S,4R)‑N‑((S)‑1‑(6‑(4‑氟‑1H‑吡唑‑1‑基)吡啶‑3‑基)乙基)‑1‑甲氧基‑4‑(4‑甲基‑6‑((5‑甲基‑1H‑吡唑‑3‑基)氨基)嘧啶‑2‑基)环己烷甲酰胺(式(I)化合物)的新晶型及其制备方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111777595A
Jurisdiction
CN
Classification
—
Expires
2020-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Acebright Pharmaceuticals Group Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.